Health Condition 1: null- proliferative phase of infantile hemangioma
Conditions
Interventions
Intervention1: drug: Propranolol
for less than 7 kg weight:
dose: 5 milligrams
frequency:twice a day (12 hourly)
route of administration: oral
for more than 7 kg weight:
dose: 5 milligrams
frequen
Sponsors
GCS Medical College and research centre
Eligibility
Inclusion criteria
Inclusion criteria: • Infants under 12 months • Presenting a hemangioma with the following characteristics: o subcutaneous and / or cutaneous o Minimum diameter of 1.5cm on face, 5cm outside face and 1cm if it is ulcerated. o without functional impairment requiring treatment or oral corticosteroid • Consent of both parents (or the person having parental authority in families)
Exclusion criteria
Exclusion criteria: age: more than 12 months. • Indication of treatment with corticosteroids for an indication other than hemangioma • Indication of treatment with beta-blocker for another indication that the hemangioma • Infant presenting contra-indications for the administration of propranolol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| efficacy will be evaluated using a VAS (visual analogue scale) on a series of photos at Day 0, Day 30, Day 60 and Day 90. It will also evaluated by size measurement by ultra-sonography(USG). safety will be evaluated at every visit by reporting all adverse eventsTimepoint: Day 0, Day 30, Day 60 and Day 90 | — |
Secondary
| Measure | Time frame |
|---|---|
| regression rate can be calculated.Timepoint: Day 0, Day 30, Day 60 and Day 90 | — |
Countries
India
Contacts
Public ContactDr Jigna Padhiyar
GCS Medical College and research centre
Outcome results
None listed